In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berkeley HeartLab: Getting It Right the Second Time

Executive Summary

One of the great mysteries that has long bewildered cardiologists is why as many people with normal cholesterol levels suffer from heart disease and sudden cardiac death as do those with elevated cholesterol. Building on technology developed at the Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley HeartLab has developed a battery of proprietary diagnostic tests that reveal cholesterol abnormalities that go beyond conventional HDL and LDL analysis. Berkeley HeartLab was founded as a cardiovascular reference lab that had a unique diagnostic approach but floundered largely because of the company's inability to convince cardiologists of the benefits of this new method over traditional cholesterol tests. A classic example of a re-start, new management appears to have unearthed the value in the company's proprietary testing program by recognizing the advantage in marketing Berkeley HeartLab's product as a cardiovascular diagnostic planning and disease management tool powered by web-enabled e-health technology.

You may also be interested in...



EU Indication Restricted For Novartis's Newly Approved Piqray

Piqray is now approved for use in 50 countries but not only did the novel breast cancer drug take longer to be approved in the EU than in the US, its indication is narrower in the EU.

Long-Awaited EU Review Questions 10-Year Orphan Exclusivity

The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."

‘Buy American’ Executive Order Receives Backlash

To build a “reliable long-term domestic production” of medicines and related supplies and to “minimize potential shortages,” US President Donald Trump has signed a ‘Buy American’ executive order. However, the move has left industry wondering if it is a sustainable solution.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel